Objective: Few randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of severe ARF. Design: Pragmatic, parallel group, randomized, controlled, multicenter trial. Setting: Non-intensive care wards of tertiary centers. Patients: Non-ICU ward patients with mild to moderate ARF without an established indication for NIV. Interventions: Patients will be randomized to receive or not receive NIV in addition to best available care. Measurements and main results: We will enroll 520 patients, 260 in each group. The primary endpoint of the study will be the development of severe ARF. Secondary endpoints will be 28-day mortality, length of hospital stay, safety of NIV in non-ICU environments, and a composite endpoint of all in-hospital respiratory complications. Conclusions: This trial will help determine whether the early use of NIV in non-ICU wards can prevent progression from mild-moderate ARF to severe ARF.
Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan
Cabrini L.;
2019-01-01
Abstract
Objective: Few randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of severe ARF. Design: Pragmatic, parallel group, randomized, controlled, multicenter trial. Setting: Non-intensive care wards of tertiary centers. Patients: Non-ICU ward patients with mild to moderate ARF without an established indication for NIV. Interventions: Patients will be randomized to receive or not receive NIV in addition to best available care. Measurements and main results: We will enroll 520 patients, 260 in each group. The primary endpoint of the study will be the development of severe ARF. Secondary endpoints will be 28-day mortality, length of hospital stay, safety of NIV in non-ICU environments, and a composite endpoint of all in-hospital respiratory complications. Conclusions: This trial will help determine whether the early use of NIV in non-ICU wards can prevent progression from mild-moderate ARF to severe ARF.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.